Gapping up
In reaction to strong earnings/guidance: APRI +19.3%, SUPN +17%, SUPN +17%, INSY +15.8%, ERB +12.2%, DTSI +11.1%, TRAK +9.9%, CUI +9%, KATE +8.7%, STRI +6.8%, (also announces strategic relationship with the Zhenfa Energy Group), UCP +5.3%, SOL +4.6%, AER +4.2%, BTX +4.2%, NOAH +3.6%, UNTD +2.9%, ICUI +2.8%, ONTY +2.6%, PUK +2.2%, VAL+2.1%, MR +1.8%, FXEN +1.8%, ARRY +1.7%, ONVO +1.7%, TRVN +1.3%, TRQ +0.9%, GNMK +0.8%, HALO +0.7%, .
M&A news: FRF +40% (to be acquired by Tiptree Financial (TIPT) for $10.00 per share).
Select financial related names showing strength: BCS +1.4%, ING +0.9%, DB +0.5%.
Other news: ICPT +48.8% (discloses results from FLINT trial of obeticholic acid in nonalcoholic steatohepatitis), APRI +19.3% (enters into common stock purchase agreement with Aspire Capital), CNAT +10.7% (ICPT sympathy), STRI +6.8% (announces strategic relationship with the Zhenfa Energy Group), EXAS +5.7% (announces the FDA has approved Cologuard, the co's noninvasive, stool DNA colorectal cancer screening test), SMG +5.4% (declared special one-time cash dividend of $2/share; approves new share repurchase authorization of $500 mln; increases quarterly dividend to $0.45/share), SSNI +4.3% ( initiated with a Outperform at Northland Capital), BWP +3.5% (positive mention on Mad Money), CEMP +3.1% (announced the initiation of a Phase 3 clinical trial, called Solitaire-U, of a single 1000 mg dose of oral solithromycin in patients with uncomplicated Neisseria gonorrhea and chlamydia infections.), ONTY +2.6% (announced acquisition of Alpine Biosciences for ~ 9.3 mln shares of common stock ($27 mln value)), ATLS +2.3% (positive mention on Mad Money), CNSL +2.2% (to replace TAYC in the S&P SmallCap 600), CIE +2.1% (Paulson & Co discloses 10.1% passive stake in 13G filing), TSL +1.9% (to develop 49.9MW solar power plant in UK), ETE +1.4% (positive mention on Mad Money), CSIQ +1.3% (modules to power 44 MW North Carolina solar farms), OPK +1% (announced Rayaldee Phase 3 trial met primary endpoints; top-line data from second identical pivotal Phase 3 trial expected in Sep 2014; NDA submission to the FDA on track for end of 2014).
Analyst comments: SKUL +6.1% (upgraded to Hold from Underperform at Jefferies), NBG +4.3% (upgraded to Buy from Neutral at Citigroup), SUNE +2.4% (reinstated with a Buy at Goldman), BC +2.1% (upgraded to Strong Buy from Mkt Perform at Raymond James), DF +2% (upgraded to Outperform from Neutral at Credit Suisse), ANF +1.9% (upgraded to Buy from Hold at Stifel), FSLR+1.5% (added to Focus List at Citigroup), KSU +0.6% (upgraded to Neutral from Underperform at Macquarie
)
In reaction to strong earnings/guidance: APRI +19.3%, SUPN +17%, SUPN +17%, INSY +15.8%, ERB +12.2%, DTSI +11.1%, TRAK +9.9%, CUI +9%, KATE +8.7%, STRI +6.8%, (also announces strategic relationship with the Zhenfa Energy Group), UCP +5.3%, SOL +4.6%, AER +4.2%, BTX +4.2%, NOAH +3.6%, UNTD +2.9%, ICUI +2.8%, ONTY +2.6%, PUK +2.2%, VAL+2.1%, MR +1.8%, FXEN +1.8%, ARRY +1.7%, ONVO +1.7%, TRVN +1.3%, TRQ +0.9%, GNMK +0.8%, HALO +0.7%, .
M&A news: FRF +40% (to be acquired by Tiptree Financial (TIPT) for $10.00 per share).
Select financial related names showing strength: BCS +1.4%, ING +0.9%, DB +0.5%.
Other news: ICPT +48.8% (discloses results from FLINT trial of obeticholic acid in nonalcoholic steatohepatitis), APRI +19.3% (enters into common stock purchase agreement with Aspire Capital), CNAT +10.7% (ICPT sympathy), STRI +6.8% (announces strategic relationship with the Zhenfa Energy Group), EXAS +5.7% (announces the FDA has approved Cologuard, the co's noninvasive, stool DNA colorectal cancer screening test), SMG +5.4% (declared special one-time cash dividend of $2/share; approves new share repurchase authorization of $500 mln; increases quarterly dividend to $0.45/share), SSNI +4.3% ( initiated with a Outperform at Northland Capital), BWP +3.5% (positive mention on Mad Money), CEMP +3.1% (announced the initiation of a Phase 3 clinical trial, called Solitaire-U, of a single 1000 mg dose of oral solithromycin in patients with uncomplicated Neisseria gonorrhea and chlamydia infections.), ONTY +2.6% (announced acquisition of Alpine Biosciences for ~ 9.3 mln shares of common stock ($27 mln value)), ATLS +2.3% (positive mention on Mad Money), CNSL +2.2% (to replace TAYC in the S&P SmallCap 600), CIE +2.1% (Paulson & Co discloses 10.1% passive stake in 13G filing), TSL +1.9% (to develop 49.9MW solar power plant in UK), ETE +1.4% (positive mention on Mad Money), CSIQ +1.3% (modules to power 44 MW North Carolina solar farms), OPK +1% (announced Rayaldee Phase 3 trial met primary endpoints; top-line data from second identical pivotal Phase 3 trial expected in Sep 2014; NDA submission to the FDA on track for end of 2014).
Analyst comments: SKUL +6.1% (upgraded to Hold from Underperform at Jefferies), NBG +4.3% (upgraded to Buy from Neutral at Citigroup), SUNE +2.4% (reinstated with a Buy at Goldman), BC +2.1% (upgraded to Strong Buy from Mkt Perform at Raymond James), DF +2% (upgraded to Outperform from Neutral at Credit Suisse), ANF +1.9% (upgraded to Buy from Hold at Stifel), FSLR+1.5% (added to Focus List at Citigroup), KSU +0.6% (upgraded to Neutral from Underperform at Macquarie
)